World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. The biggest battle arena by far is oncology. oncology therapeutics market has reached $71 billion. oncology therapeutics market has reached $71 billion. ” The U.S. ” The U.S.

Pharma 210

Pharma Food and Drug Administration Marketing Prescription 210

European Pharmaceutical Review

AUGUST 24, 2022

ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. In total, there are 14 approved ADCs on the global market, all for oncology indications, and over 140 ADCs currently in clinical development.

Engineering 80

Engineering Side effects Marketing Patients 80

PM360

OCTOBER 13, 2023

Casey Cronin Life sciences marketers have a unique opportunity to connect with target audiences on an individual level and foster brand safety through AI advancement. AI is also making waves in how to find and target patient communities as healthcare privacy legislation continues to expand in the United States.

Marketing 64

Marketing Specialization Healthcare Healthcare 64

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. All currently approved CAR-Ts are autologous, with the patient’s T-cells being genetically engineered to target antigens expressed by the cancerous cells.

Physicians 52

Physicians Marketing Patients Manufacturing 52

European Pharmaceutical Review

NOVEMBER 10, 2022

With the new modalities used to treat disease and address previously undruggable targets, advanced drug delivery systems are critical to ensure targeted delivery, and to maximise safety and efficacy. Modifying or developing targeting moieties is necessary to improve extrahepatic delivery. Figure 1 ).

Medicine 94

Medicine Distribution Engineering Electronics 94

PM360

APRIL 7, 2023

This option grows more critical as new therapies become available with price tags as high as $3.5 Analysis of Time-to-Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small-Cell Lung Cancer.” Annals of Oncology , May 2019. Endpoints News , January 20, 2023.

Manufacturing 52

Manufacturing Marketing Patients Safety 52

European Pharmaceutical Review

DECEMBER 27, 2023

Additionally, it was not recommended to use low-dose steroids or allow early administration of tocilizumab, a monoclonal antibody targeting the interleukin-6 (IL-6), in order to reduce and prevent severe CRS. This is in addition to its considerable price tag. Journal of Hematology & Oncology. Journal of Clinical Oncology.

Manufacturing 81

Manufacturing Food and Drug Administration Patients Pharma 81